Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 31 Melanoma 20 Neoplasms 13 Breast Neoplasms 11 Pancreatic Neoplasms 9 Lung Neoplasms 9 Head and Neck Neoplasms 9 Triple Negative Breast Neoplasms 8 Stomach Neoplasms 8 Squamous Cell Carcinoma of Head and Neck 8 Ovarian Neoplasms 8 Neoplasm Metastasis 8 Colorectal Neoplasms 7 Carcinoma, Renal Cell 7 Carcinoma, Hepatocellular 6 Prostatic Neoplasms 4 Hodgkin Disease 4 Glioblastoma 4 Carcinoma, Transitional Cell 4 Carcinoma 4 Uterine Cervical Neoplasms 3 Liver Neoplasms 3 Kidney Neoplasms 3 Esophageal Squamous Cell Carcinoma 3 Esophageal Neoplasms 3 Adenocarcinoma 3 Small Cell Lung Carcinoma 2 Parkinson Disease 4, Autosomal Dominant Lewy Body 2 Neoplasms, Squamous Cell 2 Mesothelioma 2

Interventions

Tamoxifen 2 pembrolizumab 1 Tretinoin 1 Tocopherols 1 Standard of Care 1 Pentoxifylline 1 Passive Cutaneous Anaphylaxis 1 Mifepristone 1 Metformin 1 Isotretinoin 1 Culture Techniques 1 Cannabidiol 1 Atorvastatin 1 Anesthesia, General 1 Anesthesia, Conduction 1 Analgesia, Patient-Controlled 1 Alitretinoin 1 Acceptance and Commitment Therapy 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Unknown × Breast Cancer Female × pembrolizumab × Clear all

NCT03879174 2019-03-18

Pembro

Mediclinic Middle East

Phase 2 Unknown

Breast Cancer Female

Data powered by HemOnc (CC BY 4.0) Colophon ⚡